Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
10Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
CNS Pharmaceuticals, Inc. (CNSP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
28Total relationships
3Distinct source URLs
20High confidence
0.849Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
CNS Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CORTICE-BIOSCIENCES-INC
CORTICE-BIOSCIENCES-INC
92%
The Company entered into an Exclusive License Agreement with Cortice Biosciences, Inc. pursuant to which Cortice granted the Company an exclusive license to the intellectual property rights
ANIMAL-LIFE-SCIENCES-LLC
ANIMAL-LIFE-SCIENCES-LLC
90%
10.6 Sublicense Agreement between CNS Pharmaceuticals, Inc. and Animal Life Sciences, LLC. dated August 31, 2018
HOUSTON-PHARMACEUTICALS-INC
HOUSTON-PHARMACEUTICALS-INC
90%
10.1 Amended And Restated Patent License Agreement effective as of December 28, 2017 between CNS Pharmaceuticals, Inc. and Houston Pharmaceuticals, Inc.
REATA-PHARMACEUTICALS-INC
REATA-PHARMACEUTICALS-INC
90%
10.2 Collaboration and Asset Purchase Agreement between CNS Pharmaceuticals, Inc. and Reata Pharmaceuticals, Inc. dated November 21, 2017
WPD-PHARMACEUTICALS-INC
WPD-PHARMACEUTICALS-INC
90%
10.5 Sublicense Agreement between CNS Pharmaceuticals, Inc. and WPD Pharmaceuticals, Inc. dated August 30, 2018
CNS Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
A-G-P-ALLIANCE-GLOBAL-PARTNERS
A-G-P-ALLIANCE-GLOBAL-PARTNERS
90%
10.27 Placement Agency Agreement between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners
CORTICE-BIOSCIENCES-INC
CORTICE-BIOSCIENCES-INC
90%
10.25 Stock Purchase Agreement between CNS Pharmaceuticals, Inc. and Cortice Biosciences, Inc.
& Oncology Neurological disorders represent a staggering public health crisis of global proportions. The World Health Organization (“WHO”) and the Global Burden of Disease study identify neurological…
Reciprocal relationship from ATNM graph: Reciprocal relationship from CNSP graph: & Oncology Neurological disorders represent a staggering public health crisis of global proportions. The World Health…
Reciprocal relationship from BDRX graph: Reciprocal relationship from CNSP graph: Reciprocal relationship from BDRX graph: ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and …
ASTELLAS-PHARMA-INC
ASTELLAS-PHARMA-INC
62%
& Oncology Neurological disorders represent a staggering public health crisis of global proportions. The World Health Organization (“WHO”) and the Global Burden of Disease study identify neurological…
Reciprocal relationship from ASTS graph: Reciprocal relationship from CNSP graph: Reciprocal relationship from ASTS graph: Reciprocal relationship from CNSP graph: Reciprocal relationship from ASTS g…
FORGE-FINANCIAL-GROUP
FORGE-FINANCIAL-GROUP
62%
& Oncology Neurological disorders represent a staggering public health crisis of global proportions. The World Health Organization (“WHO”) and the Global Burden of Disease study identify neurological…
PROTEA-BIOSCIENCES-GROUP-INC
PROTEA-BIOSCIENCES-GROUP-INC
62%
& Oncology Neurological disorders represent a staggering public health crisis of global proportions. The World Health Organization (“WHO”) and the Global Burden of Disease study identify neurological…
SCHERING-AG
SCHERING-AG
62%
& Oncology Neurological disorders represent a staggering public health crisis of global proportions. The World Health Organization (“WHO”) and the Global Burden of Disease study identify neurological…
CNS Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CNSP-DEBT-8753
Warrants outstanding: 0.001
90%
xbrl warrant detail from xbrl 2025-12-31.
CNSP-DEBT-8754
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
CNSP-DEBT
Debt stack $449,874
90%
Market cache reports total debt of $449,874.
CNS Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for CNS Pharmaceuticals, Inc..
CNS Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
CNSP-OWNER-BARRETT-COMPANY-INC
Barrett & Company, Inc.
95%
13F/ownership overlay lists Barrett & Company, Inc. ; shares held 8; value $58; as of 2026-03-31.
CNSP-OWNER-BANK-OF-AMERICA-CORPORATION
Bank of America Corporation
95%
13F/ownership overlay lists Bank of America Corporation; shares held 4; value $29; as of 2025-12-31.
CNSP-OWNER-UBS-GROUP-AG
UBS Group AG
95%
13F/ownership overlay lists UBS Group AG; shares held 729; ownership 0.09%; value $5,314; as of 2026-03-31.
CNSP-OWNER-IKARIAN-CAPITAL-LLC
Ikarian Capital, LLC
95%
13F/ownership overlay lists Ikarian Capital, LLC; shares held 45,830; ownership 5.65%; value $334,100; as of 2025-12-31.
CNSP-OWNER-SOUND-INCOME-STRATEGIES-LLC
Sound Income Strategies, LLC
95%
13F/ownership overlay lists Sound Income Strategies, LLC; shares held 16; value $116; as of 2026-03-31.
CNSP-OWNER-DRW-SECURITIES-LLC
DRW Securities, LLC
95%
13F/ownership overlay lists DRW Securities, LLC; shares held 15,429; ownership 1.90%; value $112,477; as of 2025-12-31.
CNSP-OWNER-STONEPINE-CAPITAL-MANAGEMENT-LLC
Stonepine Capital Management, LLC
95%
13F/ownership overlay lists Stonepine Capital Management, LLC; shares held 48,827; ownership 6.02%; value $355,948; as of 2025-12-31.
CNSP-OWNER-BOOTHBAY-FUND-MANAGEMENT-LLC
Boothbay Fund Management, LLC
95%
13F/ownership overlay lists Boothbay Fund Management, LLC; shares held 13,524; ownership 1.67%; value $98,589; as of 2025-12-31.
CNSP-OWNER-DANSKE-BANK-A-S
Danske Bank A/s
95%
13F/ownership overlay lists Danske Bank A/s; shares held 1; value $7; as of 2025-12-31.
CNSP-OWNER-MAI-CAPITAL-MANAGEMENT
MAI Capital Management
95%
13F/ownership overlay lists MAI Capital Management; shares held 3; value $21; as of 2025-12-31.
CNS Pharmaceuticals, Inc. Extended Supply Chain Network
